New Hepatitis C Treatment

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email
Vosevi™, a new single tablet treatment for hepatitis C (HCV), combines 2 previously approved drugs, sofosbuvir and velpatasvir, and a new drug, voxilaprevir. It is approved for patients with chronic HCV of any genotype (1-6), with or without mild liver disease, who have failed treatment (eg, relapsed) with sofosbuvir or a NS5A inhibitor (ledipasvir, ombitasvir, daclatasvir, elbasvir, velpatasvir). Vosevi™ has not yet been incorporated into HCV treatment guidelines; however, its place in therapy will likely be for the most difficult-to-treat patients.

In trials with Vosevi™, virus was cleared from the blood in 96–97% of patients who failed previous HCV treatment. The recommended dose is 1 tablet (containing 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir) daily for 12 weeks. The most common side effects, occurring in more than 10% of patients, are headache, fatigue, diarrhea and nausea. Like many other HCV medications, Vosevi™ cannot be used with rifampin and there are many other potential drug interactions – review the package insert and patients’ current medication list carefully.

References:

More To Explore

What is The Rx Consultant?

The Rx Consultant is a subscription-based service that delivers practical updates & reviews covering all the top-selling drugs and common health conditions. All our publications focus on the facts busy front-line pharmacists and other health care practitioners need to stay current, and provide it a streamlined, easy reading style.

For 30 years The Rx Consultant has operated independent of the pharmaceutical industry and has no commercial bias.

Join thousands of healthcare providers who enjoy the following benefits every month.

1. Drug Therapy Updates & Reviews

The eLibrary contains over 30 streamlined updates on drug therapy for the most common diseases. New articles are added every month – it is a continually expanding resource.

2. Continuing Education

The eLibrary includes 50+ hours of Pharmacology CE from an ACPE approved provider at no additional charge. Each article provides at least 1.5 hours of Pharmacology CE. Subscribers can take their tests online, score them immediately, then print or save their credit statements. Pharmacology CE tests can also be mailed, faxed, or even phoned in to The Rx Consultant office, and credit statements will be delivered by mail or fax.

3. Unlimited Access to our Resource Library, with:

  • Healthcare News

    The eLibrary includes a news column covering the developments that matter most to nurse practitioners and other front-line providers. You get a headline, the bottom line, and how it’s likely to affect your practice in a few short lines, then it’s on to the next news item. The news briefs are also available in print monthly as Rx News Connection.
  • Patient Education Pages

    Patient Q&A to sharpen your skills in educating patients and answering common questions.
  • Charts & Tables

    At-a-glance updates on drugs, doses, common side effects & interactions
  • Quick Facts

    Key facts organized for fast access both online and on handy reference cards.
  • The Bottom Line

    Our members suggest the topics and each issue undergoes a rigorous three month peer reviewed process. Our CE is different because we accept no grants, advertising, or funding of any kind from drug manufacturers. With no financial ties, maintaining a bias-free publication is a straightforward process.

The Rx Consultant maintains a high standard for quality

And a rigorous system for content development that insures it. Every issue is written by an expert in the topic area, and then peer reviewed, fact-checked and edited to insure that the content is

  • Evidence-based
  • Non-Biased
  • Balanced
  • Timely
  • Accurate and
  • Useful for community practitioners

The Rx Consultant is completely independent of the pharmaceutical industry.

We accept no grants, advertising, or funding of any kind from drug manufacturers. With no financial ties, maintaining a bias-free publication is a straightforward process.